VGXI is a contract manufacturer of plasmid DNA. The company delivers flexibility, experience, reliability, and value to clients’ challenging programs. The company’s cGMP and non-cGMP products have passed rigorous international regulatory reviews.

Adastra Pharmaceuticals is a private, clinical-stage biopharmaceutical company committed to providing responsible solutions to advance patient care in oncology. Its vision is to identify, develop, and deliver to patients important new therapies for diseases with significant unmet needs. This commitment is epitomized by its lead clinical candidate, zotiraciclib, which is initially being developed for the treatment of high-grade gliomas (HGG) and diffuse intrinsic pontine glioma (DIPG), two forms of brain cancer characterized by Myc overexpression. Adastra possesses a rich history of institutional and academic collaboration, including ongoing clinical research programs with the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC).

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

Founded in early 2002 by Avalon Ventures and Domain Associates, Ansata Therapeutics is developing & commercializing novel medicines that capitalize on the Company's industry- leading expertise and intellectual property in molecular transduction. Ansata has several preclinical programs under development in the oncology and neurodegenerative disease areas. The company strives to rapidly advance lead compounds from late-stage preclinical research into clinical development by leveraging its proprietary knowledge of common dermatological diseases.

OcuCure Therapeutics is an ophthalmic pharmaceutical company developing new drugs. The company's lead compound has been formulated as a topical eye drop for both Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR). AMD and DR are leading causes of blindness in developed countries. Additionally, the lead compound has potential for use as a prophylactic. The presence of the therapeutic target has been validated in human AMD and DR tissues. This confirms the OcuCure approach for treating ocular angiogensis. The topical eye drop also has demonstrated the ability to cross human corneas in in vitro studies. When the eye drop was administered to animals, the lead compound penetrated all the way back to the retina at clinically significant concentrations without any toxic effects observed. By comparison, the currently available drugs for AMD are administered by a monthly injection into the eye.

Metronome Therapeutics is developing oncology drugs